Evidence mapPaperPMID 32280378Full record

ReviewDiabetology & metabolic syndrome2020

Melatonin: new insights on its therapeutic properties in diabetic complications.

Mohammad Hossein Pourhanifeh, Azam Hosseinzadeh, Ehsan Dehdashtian, Karim Hemati, Saeed Mehrzadi

Open access · goldAbstract readReview
In one paragraph

Review in Diabetology & metabolic syndrome, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 3 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 3 syntheses or guidelines pooled it, 97 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Mohammad Hossein PourhanifehHalal Research Center of IRI, FDA, Tehran, Iran.
Azam Hosseinzadeh2Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran.
Ehsan Dehdashtian3School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Karim Hemati4Department of Anesthesiology, Iran University of Medical Sciences, Tehran, Iran.
Saeed Mehrzadi2Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran.
Iran University of Medical Sciences · IRNiroo Research Institute · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes and diabetic complications are considered as leading causes of both morbidity and mortality in the world. Unfortunately, routine medical treatments used for affected patients possess undesirable side effects, including kidney and liver damages as well as gastrointestinal adverse reactions. Therefore, exploring the novel therapeutic strategies for diabetic patients is a crucial issue. It has been recently shown that melatonin, as main product of the pineal gland, despite its various pharmacological features including anticancer, anti-aging, antioxidant and anti-inflammatory effects, exerts anti-diabetic properties through regulating various cellular mechanisms. The aim of the present review is to describe potential roles of melatonin in the treatment of diabetes and its complications.

Indexed as

CardiomyopathyDiabetes mellitusHyperglycemiaInflammationLipid metabolismMelatoninNephropathyNeuropathyOxidative stressRetinopathy

Identifiers

PMID32280378
PMCPMC7140344
OpenAlexW3015421474

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.